Insight

Yüksel Ürün: Omitting the 5-FU bolus from regimens in metastatic GI cancers may reduce toxicity without impacting overall survival

Photo taken from Yüksel Ürün/X

Sep 12, 2024, 17:16

Yüksel Ürün: Omitting the 5-FU bolus from regimens in metastatic GI cancers may reduce toxicity without impacting overall survival

Yüksel Ürün shared on X:

“Omitting the 5-FU bolus from regimens like FOLFOX, FOLFIRI, and FOLFIRINOX in metastatic GI cancers may reduce toxicity without impacting overall survival.”

GI cancers

Omission of 5-Fluorouracil Bolus From Multidrug Regimens for Advanced Gastrointestinal Cancers: A Multicenter Cohort Study

Authors: Chengwei Peng, Saad Saffo, Paul E. Oberstein, Michael Shusterman, Charlene Thomas, Daniel J. Becker, Jordan D. Berlin, Lawrence P. Leichman, Ben Boursi, Anil B. Nagar, Shun Yu

Yüksel Ürün: Omitting the 5-FU bolus from regimens in metastatic GI cancers may reduce toxicity without impacting overall survival

Source: Yüksel Ürün/X

More posts featuring Yüksel Ürün on oncodaily.com

Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.

5-FU Anil B. Nagar Ben Boursi cancer Charlene Thomas Chengwei Peng Daniel J. Becker Jordan D. Berlin Lawrence P. Leichman metastatic GI cancers Michael Shusterman OncoDaily Oncology Paul E. Oberstein Saad Saffo Shun Yu Yüksel Ürün

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Former Disney CEO Bob Chapek Appointed Senior Adviser at SCAN Group

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage